CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 80 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $416 | -98.2% | 14 | -98.3% | 0.00% | – |
| Q4 2021 | $23,000 | -98.7% | 843 | -99.0% | 0.00% | -100.0% |
| Q3 2021 | $1,748,000 | +720.7% | 83,104 | +493.6% | 0.00% | – |
| Q1 2021 | $213,000 | +52.1% | 14,001 | +40.3% | 0.00% | – |
| Q4 2020 | $140,000 | +677.8% | 9,982 | +731.8% | 0.00% | – |
| Q3 2020 | $18,000 | -81.6% | 1,200 | -78.6% | 0.00% | – |
| Q2 2020 | $98,000 | – | 5,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 820,720 | $17,276,000 | 7.15% |
| 5AM Venture Management, LLC | 1,362,286 | $28,676,000 | 5.82% |
| Bain Capital Life Sciences Investors, LLC | 1,679,701 | $35,358,000 | 2.19% |
| Opaleye Management Inc. | 402,113 | $8,464,000 | 1.58% |
| FRAZIER MANAGEMENT LLC | 851,306 | $17,920,000 | 1.43% |
| Perceptive Advisors | 3,963,517 | $83,432,000 | 1.21% |
| Altium Capital Management LP | 193,000 | $4,063,000 | 1.07% |
| MPM BioImpact LLC | 298,392 | $6,281,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 548,643 | $11,549,000 | 0.97% |
| Ghost Tree Capital, LLC | 150,000 | $3,158,000 | 0.92% |